Literature DB >> 10582167

A role for cytokines in potentiation of malaria vaccines through immunological modulation of blood stage infection.

A W Taylor-Robinson1, E C Smith.   

Abstract

Malaria is the world's major parasitic disease, for which effective control measures are urgently needed. One of the difficulties hindering successful vaccine design against Plasmodium is an incomplete knowledge of antigens eliciting protective immunity, the precise types of immune response for which to aim, and how these can be induced. A greater appreciation of the mechanisms of protective immunity, on the one hand, and of immunopathology, on the other, should provide critical clues to how manipulation of the immune system may best be achieved. We are studying the regulation of the balance between T helper 1 (Th1) and T helper 2 (Th2) CD4+ T lymphocytes in immunity to asexual blood stages of malaria responsible for the pathogenicity of the disease. Protective immunity to the experimental murine malarias Plasmodium chabaudi and Plasmodium yoelii involves both Th1 and Th2 cells, which provide protection by different mechanisms at different times of infection characterised by higher and lower parasite densities, respectively. This model therefore facilitates a clearer understanding of the Th1/Th2 equilibrium that appears central to immunoregulation of all host/pathogen relationships. It also permits a detailed dissection in vivo of the mechanisms of antimalarial immunity. Here, we discuss the present state of malaria vaccine development and our current research to understand the factors involved in the modulation of vaccine-potentiated immunity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10582167     DOI: 10.1111/j.1600-065x.1999.tb01344.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  9 in total

1.  Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.

Authors:  Asma Abdullah Nurul; Mohd Nor Norazmi
Journal:  Parasitol Res       Date:  2010-11-06       Impact factor: 2.289

2.  Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.

Authors:  Karen A Near; Anthony W Stowers; Dragana Jankovic; David C Kaslow
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria.

Authors:  Anthony W Stowers; Michael C Kennedy; Brian P Keegan; Allan Saul; Carole A Long; Louis H Miller
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

4.  Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine.

Authors:  T Scorza; K Grubb; P Smooker; A Rainczuk; D Proll; T W Spithill
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

5.  Cerebral malaria in mice: interleukin-2 treatment induces accumulation of gammadelta T cells in the brain and alters resistant mice to susceptible-like phenotype.

Authors:  A Haque; H Echchannaoui; R Seguin; J Schwartzman; L H Kasper; S Haque
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

6.  Tomatine adjuvantation of protective immunity to a major pre-erythrocytic vaccine candidate of malaria is mediated via CD8+ T cell release of IFN-gamma.

Authors:  Karen G Heal; Andrew W Taylor-Robinson
Journal:  J Biomed Biotechnol       Date:  2010-03-11

7.  Antibodies to Plasmodium falciparum glycosylphosphatidylinositols: inverse association with tolerance of parasitemia in Papua New Guinean children and adults.

Authors:  Craig S Boutlis; D Channe Gowda; Ramachandra S Naik; Graeme P Maguire; Charles S Mgone; Moses J Bockarie; Moses Lagog; Erwin Ibam; Kerry Lorry; Nicholas M Anstey
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

Review 8.  Immunity to liver stage malaria: considerations for vaccine design.

Authors:  Andrew W Taylor-Robinson
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

9.  The mechanism and significance of deletion of parasite-specific CD4(+) T cells in malaria infection.

Authors:  Huji Xu; Jiraprapa Wipasa; Huaru Yan; Ming Zeng; Morris O Makobongo; Fred D Finkelman; Anne Kelso; Michael F Good
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.